Get the Stockscreener App
697.05
4.53%
30.20
After Hours:
697.05
Regeneron Pharmaceuticals Inc stock is traded at $697.05, with a volume of 1.62M.
It is up +4.53% in the last 24 hours and down -2.94% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$666.85
Open:
$650
24h Volume:
1.62M
Relative Volume:
1.90
Market Cap:
$76.60B
Revenue:
$13.85B
Net Income/Loss:
$4.65B
P/E Ratio:
17.25
EPS:
40.41
Net Cash Flow:
$3.32B
1W Performance:
+1.56%
1M Performance:
-2.94%
6M Performance:
-35.59%
1Y Performance:
-26.25%
1-Day Range:
$642.00
$709.98
1-Week Range:
$642.00
$709.98
52-Week Range:
$642.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron (REGN) Shares Surge on Strong Earnings Report - GuruFocus.com
Regeneron Reports Strong Growth and Promising Pipeline - TipRanks
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday - The Motley Fool
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Morgan Stanley cuts Regeneron stock price target to $1,150 - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid QuarterEylea To Strike Back In 2025 - Seeking Alpha
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend - Yahoo Finance
Latest Federal Court Cases: Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. - JD Supra
Regeneron Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
Strong 4th-qtr and full year financials from Regeneron - The Pharma Letter
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $903.00 Price Target at BMO Capital Markets - MarketBeat
Regeneron holds off copies of $6bn eye treatment - Life Sciences Intellectual Property Review
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs - FiercePharma
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,030.00 Price Target at TD Cowen - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Bernstein Bank - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $862.00 Price Target at Leerink Partners - MarketBeat
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Yahoo! Voices
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends - BioSpace
Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds? - Insider Monkey
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by E. Ohman J or Asset Management AB - MarketBeat
Regeneron: Q4 Earnings Snapshot - Thehour.com
Regeneron beats quarterly estimates on eczema drug demand - PharmaLive
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates - MSN
Regeneron Advances On Fourth-Quarter Beat As Eylea Meets Expectations - Inkl
Regeneron Pharmaceuticals, Inc. Declares Quarterly Dividend of $0.88 (NASDAQ:REGN) - MarketBeat
Regeneron Soars With Strong Eczema Drug Demand And Robust Earnings - Finimize
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program - Yahoo Finance
Regeneron Beats Quarterly Estimates on Eczema Drug Demand; Launches Dividend Program - U.S News & World Report Money
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Regeneron’s earnings boosted by demand for blockbuster eye drug Eylea - MarketWatch
Regeneron Pharmaceuticals Q4 2024 Earnings: Revenue Beats at $3. - GuruFocus.com
Calamos Advisors LLC Purchases 10,523 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron will start delivering quarterly dividends 37 years into its existence - Endpoints News
abrdn plc Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron 4Q Rev Up on Strong Sales of EYLEA HD - MarketWatch
Regeneron: Q4 Earnings Snapshot -February 04, 2025 at 06:55 am EST - Marketscreener.com
Regeneron shares rise as Q4 earnings top estimates By Investing.com - Investing.com Canada
Regeneron Launches Dividend Program, Boost Stock Buybacks - MarketWatch
Regeneron shares rise as Q4 earnings top estimates - Investing.com India
Regeneron Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise -- Shares Up Pre-Bell - Marketscreener.com
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN - ACCESS Newswire
Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion - The Manila Times
Leerink Partnrs Issues Positive Outlook for REGN Earnings - MarketBeat
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN - PR Newswire
Regeneron's SWOT analysis: biotech giant's stock faces eylea challenges, pipeline promise - Investing.com
Regeneron Pharmaceuticals (REGN) Expected to Announce Earnings on Friday - MarketBeat
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Regeneron - GlobeNewswire
(REGN) Long Term Investment Analysis - Stock Traders Daily
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN - GlobeNewswire Inc.
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):